[{"id":"6bb1edff-f3e6-46a7-a9e0-e5a2bfe3f8ab","acronym":"EDGE-Gastric","url":"https://clinicaltrials.gov/study/NCT05329766","created_at":"2023-01-23T16:59:58.940Z","updated_at":"2024-07-02T16:34:38.031Z","phase":"Phase 2","brief_title":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","source_id_and_acronym":"NCT05329766 - EDGE-Gastric","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • Yutuo (zimberelimab) • leucovorin calcium • domvanalimab (AB154) • quemliclustat (AB680)"],"overall_status":"Recruiting","enrollment":" Enrollment 360","initiation":"Initiation: 06/10/2022","start_date":" 06/10/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-06-05"}]